Cancer Research UK Science and Innovation, shared a post on LinkedIn:
“We’ve had another day of exceptional science at the Pancreatic Cancer Conference 2026, with stand-out moments and takeaways including:
New insights into how microenvironments evolve across the disease continuum – from PanIN lesions and primary tumours (Marina Pasca) to metastatic sites (Michael Schmid).
Exciting examples of cutting-edge technologies accelerating discovery, including an AI model trained to predict spatial transcriptomics directly from histological images (Brian Brown).
A thought-provoking transatlantic panel, chaired by Anirban Maitra, exploring key questions in the rapidly evolving landscape of RAS inhibitors, including how to prioritise the most promising combination approaches and address disparities in patient access to these emerging therapies.
Our ‘beyond KRAS’ session highlighted the latest advancements in targeting other key pathways in pancreatic cancer, including hot-off-the-press data from the OMO-103 trial targeting “undruggable” MYC (Laura Soucek).
Thank you to all of today’s speakers for sharing new data and sparking discussion as this community collectively works to accelerate progress for people affected by pancreatic cancer around the world.
We’ll be back tomorrow for a final day of science digging into the latest research in early detection and interception, systemic disruptions and more.”
Other articles about Pancreatic Cancer on OncoDaily.
